ATA79592A - Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen - Google Patents

Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen

Info

Publication number
ATA79592A
ATA79592A AT0079592A AT79592A ATA79592A AT A79592 A ATA79592 A AT A79592A AT 0079592 A AT0079592 A AT 0079592A AT 79592 A AT79592 A AT 79592A AT A79592 A ATA79592 A AT A79592A
Authority
AT
Austria
Prior art keywords
domethyl
optically active
dihydropyride
dihydropyridines
cyclodextrin
Prior art date
Application number
AT0079592A
Other languages
English (en)
Other versions
AT399718B (de
Inventor
Darja Mag In Fercej-Temeljotov
Janko Dr Ing Zmitek
Breda Mag Ing Husu-Kovacevic
Sonja Dipl Ing Kotnik
Zdenka Dipl In Jerala-Strukelj
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Priority to AT0079592A priority Critical patent/AT399718B/de
Priority to SI9300199A priority patent/SI9300199A/sl
Priority to EP93106236A priority patent/EP0566142A1/de
Priority to JP5090036A priority patent/JPH06100537A/ja
Publication of ATA79592A publication Critical patent/ATA79592A/de
Priority to US08/357,790 priority patent/US5519012A/en
Application granted granted Critical
Publication of AT399718B publication Critical patent/AT399718B/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT0079592A 1992-04-16 1992-04-16 Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen AT399718B (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT0079592A AT399718B (de) 1992-04-16 1992-04-16 Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
SI9300199A SI9300199A (sl) 1992-04-16 1993-04-15 Inkluzijski kompleksi opticno aktivnih in racemnih 1,4-dihidropiridinov z metil-beta-ciklodekstrinom ali drugimi derivati ciklodekstrina, postopek za pripravo opticno aktivnih dihidropiridinov in njihovih inkluzijskih kompleksov, farmacevtski sestavki, ki vsebujejo te komplekse, in uporaba teh kompleksov
EP93106236A EP0566142A1 (de) 1992-04-16 1993-04-16 Inklusion-Komplexe von optisch aktiven und racemischen 1,4-Dihydropyridinederivate mit Zyklodextrin
JP5090036A JPH06100537A (ja) 1992-04-16 1993-04-16 光学活性でラセミ形の１，４−ジヒドロピリジンとメチル−β−シクロデキストリン又は他のシクロデキストリン誘導体との包接錯体、光学活性のジヒドロピリジン及びこれの包接錯体の製造方法、該錯体を含有する医薬組成物及び該錯体の使用
US08/357,790 US5519012A (en) 1992-04-16 1994-12-16 Inclusion complexes of optically active 1,4-dihydropyridines with methyl-β-cyclodextrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0079592A AT399718B (de) 1992-04-16 1992-04-16 Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen

Publications (2)

Publication Number Publication Date
ATA79592A true ATA79592A (de) 1994-11-15
AT399718B AT399718B (de) 1995-07-25

Family

ID=3499943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0079592A AT399718B (de) 1992-04-16 1992-04-16 Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen

Country Status (5)

Country Link
US (1) US5519012A (de)
EP (1) EP0566142A1 (de)
JP (1) JPH06100537A (de)
AT (1) AT399718B (de)
SI (1) SI9300199A (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
WO2002056883A1 (en) * 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
JP2002254554A (ja) * 2001-02-27 2002-09-11 Asahi Denka Kogyo Kk デオキシリボ核酸材料
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
NZ572225A (en) 2006-04-18 2011-05-27 Ekr Therapeutics Inc Pre-mixed pharmaceutical compositions comprising nicardipine, a tonicity agent, and a buffer
EP3807892A1 (de) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Verfahren zur senkung des blutdrucks mit einer dihydropyridinartigen pharmazeutischen zusammensetzung als calciumkanalblocker
US11103528B1 (en) 2019-07-18 2021-08-31 United States Of America As Represented By The Secretary Of The Air Force Slow release calcium composition
US11135208B2 (en) * 2019-08-12 2021-10-05 American Regent, Inc. 1,4-dihydropyridine compositions, methods of making and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
JP2603240B2 (ja) * 1987-03-09 1997-04-23 バイエル薬品株式会社 ジヒドロピリジン−ヒドロキシプロピルシクロデキストリン包接複合体
SI8810082A8 (en) * 1988-01-18 1995-12-31 Lek Tovarna Farmacevtskih Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
JPH01319502A (ja) * 1988-06-21 1989-12-25 Showa Denko Kk シクロデキストリン誘導体及びその製造方法
US5064944A (en) * 1989-09-12 1991-11-12 Advanced Separation Technologies Inc. Chiral separation media
WO1991013100A1 (en) * 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications

Also Published As

Publication number Publication date
EP0566142A1 (de) 1993-10-20
AT399718B (de) 1995-07-25
SI9300199A (sl) 1993-12-31
US5519012A (en) 1996-05-21
JPH06100537A (ja) 1994-04-12

Similar Documents

Publication Publication Date Title
DE59404480D1 (de) Fullerenderivate, verfahren zur herstellung und deren verwendung
ATA79592A (de) Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
ATE166049T1 (de) Phthalimidoperoxihexansäure, verfahren zu deren herstellung und deren verwendung
DE68907057D1 (de) Naehrstoffzusammensetzung und verfahren zu deren herstellung.
DE69131627D1 (de) Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
DE59510597D1 (de) 3-aryl-tetronsäure-derivate, deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
ATA122485A (de) Verfahren zur herstellung von neuen 1,4-dihydro-4-oxonaphthyridin-derivaten und deren salzen
DE3762846D1 (de) Optisch aktive tolanderivate und verfahren zu deren herstellung.
DE3687021D1 (de) Pyridazinonderivate, verfahren zu deren herstellung und insekttoetende zusammenstellungen.
DE68907502D1 (de) Zahnbuerste mit langsamer abgabe von desinfizierenden und anti-bakteriellen mitteln und verfahren zu deren herstellung.
DE69400334D1 (de) Diaminsalze von clavulansäure
ATA50989A (de) Antiviral und immunstimulierend wirkende neue salze, sowie verfahren zu deren herstellung und verwendung der salze
ATA260590A (de) Glyzerinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
ATA901686A (de) Kosmetische mittel mit hautberuhigender und hautregenerierender wirkung und verfahren zu deren herstellung
DE3886936D1 (de) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
DE69508962D1 (de) Diclavulanat-salze mit diaminoether und verfahren zu deren herstellung
ATE136299T1 (de) Verfahren zur herstellung der racemischen und optisch aktiven 1,2,3,4-tetrahydroisochinolin-3- carbonsäure sowie deren vorprodukte
DE59402216D1 (de) Fullerenderivate, Verfahren zur Herstellung und deren Verwendung
DE69225111D1 (de) Aufzeichnungsplatte mit verbesserter Nabenverbindung und Verfahren zu deren Herstellung
DE69217277D1 (de) Butyrsäurederivate und deren Verwendung bei der Herstellung von optisch aktivem Cyclohexylnorstatin
DE3670491D1 (de) Pyrazinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen mit diesen.
ATA307579A (de) Verfahren zur herstellung neuer, optisch aktiver oder racemischer 6,7-benzomorphan-derivate und deren saeureadditionssalze
DE58903252D1 (de) Monoformylierte 3,3'-diaminodipropylamine, ein verfahren zu deren herstellung und deren verwendung.
DE58900078D1 (de) Verfahren zur herstellung von fluormalonsaeure und ihren derivaten.
DE68914306D1 (de) Fluorenthaltende Polymerverbindung und Verfahren zur Herstellung davon.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee